If You Invested in GRAY (GRAY)

Graybug Vision, Inc. (historically trading under the Nasdaq symbol GRAY) was a clinical-stage biopharmaceutical company focused on developing medicines for ocular diseases. According to multiple company disclosures, Graybug concentrated on vision‑threatening conditions affecting the retina, optic nerve, and cornea, using approaches such as injectable sustained‑release formulations and gene therapies. The company stated that it was founded in 2011 based on technology licensed from the Johns Hopkins University School of Medicine and maintained offices in Redwood City, California and Baltimore, Maryland.

Graybug described itself as having a diversified portfolio of investigational candidates aimed at maintaining effective drug levels in ocular tissues for extended periods or addressing disease through gene therapy. Its most advanced drug candidate was GB‑102, a microparticle formulation of the pan‑VEGF inhibitor sunitinib for the treatment of wet age‑related macular degeneration, designed for intravitreal injection twice per year. Company materials also noted that GB‑102 had potential to benefit patients with diabetic retinopathy.

Another key program was GB‑401, characterized as a first‑in‑class implant formulation containing a novel prodrug of timolol for the treatment of primary open‑angle glaucoma (POAG). Graybug reported that GB‑401 was designed for twice‑per‑year intravitreal injection using a proprietary applicator and was evaluated in preclinical work presented at ophthalmology research meetings.

Graybug’s pipeline also included gene therapy and additional sustained‑release candidates. GB‑501 is described in company communications as an adeno‑associated virus (AAV) gene therapy with Orphan Drug Designation and Rare Pediatric Disease Designation for treating corneal clouding caused by mucopolysaccharidosis type 1 (MPS1), a lysosomal storage disorder. The company also referenced GB‑601, a long‑acting formulation of a novel cGMP analog intended for inherited or hereditary retinal diseases such as retinitis pigmentosa, and GB‑701, a long‑acting formulation of a potent factor B inhibitor targeting the complement cascade implicated in age‑related macular degeneration or geographic atrophy.

In a series of press releases, Graybug reported that it was conducting and planning clinical trials around these programs, including a Phase 2b trial of GB‑102 in wet age‑related macular degeneration (the ALTISSIMO trial) and preparations for additional Phase 2 work, as well as preclinical and early‑stage development for GB‑401, GB‑501, GB‑601, and GB‑701. The company also disclosed participation in ophthalmology and retina‑focused scientific meetings where it presented updates on its pipeline.

During 2022, Graybug announced a review of strategic alternatives, indicating that its board of directors was evaluating options such as an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions. Subsequent financial updates described cost‑containment measures and, by August 2022, the termination of development activities for GB‑102 and GB‑401, with GB‑501 and GB‑701 remaining at preclinical or earlier stages. These disclosures characterized Graybug as having been historically focused on ocular drug development while it evaluated strategic options.

A later announcement detailed a definitive merger agreement between Graybug Vision, Inc. and CalciMedica Inc., an all‑stock transaction intended to create a Nasdaq‑listed, clinical‑stage biopharmaceutical company centered on CalciMedica’s pipeline for life‑threatening inflammatory diseases. Company statements explained that the combined entity would focus on CalciMedica’s lead product candidate Auxora, a proprietary intravenous CRAC channel inhibitor being developed for conditions such as acute pancreatitis and asparaginase‑associated pancreatitis. Following this transaction, Graybug equity holders were expected to own a minority portion of the combined company.

Graybug later announced that it had changed its name to CalciMedica, Inc. and that its trading symbol had changed from GRAY to CALC on the Nasdaq Global Market. The company indicated that the name and symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica. As a result, the GRAY ticker primarily represents the historical identity and activities of Graybug Vision, Inc., while ongoing operations and trading are associated with CalciMedica, Inc. under the symbol CALC.

Historical focus and therapeutic areas

Across its disclosures, Graybug consistently described its focus on ocular diseases, including wet age‑related macular degeneration, diabetic retinopathy, primary open‑angle glaucoma, inherited retinal diseases such as retinitis pigmentosa, and corneal clouding related to mucopolysaccharidosis type 1. The company’s approach combined sustained‑release intravitreal formulations of small molecules and implants with gene therapy strategies, reflecting an emphasis on long‑acting treatments and potential one‑time interventions in ophthalmology.

With the merger and subsequent name and ticker change to CalciMedica, Inc. (CALC), the business focus described in later communications shifted to therapies for life‑threatening inflammatory diseases using CRAC channel inhibition. However, for investors and researchers examining the GRAY symbol, the primary relevance is Graybug Vision’s historical work in ophthalmology and its transition through strategic review and merger into the CalciMedica platform.

Company status and ticker transition

According to the name and trading symbol change announcement, Graybug Vision, Inc. changed its name to CalciMedica, Inc., and its common stock began trading on the Nasdaq Global Market under the symbol CALC. This means that GRAY functions as a historical ticker associated with Graybug Vision’s prior listing and activities. For current information on the combined company’s pipeline and strategy, investors are directed in company communications to the CalciMedica, Inc. identity and the CALC symbol on Nasdaq.